NCT07572903 The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease
| NCT ID | NCT07572903 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Anhui Medical University |
| Condition | Parkinson s Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-05-06 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-05-06 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aimed to observe the clinical efficacy and safety of single-target transcranial temporal stimulation (tTIS) intervention in Parkinson's disease (PD) patients and explore the neurophysiological mechanism of TIS intervention. The study was designed as a three-arm (A: GPi group, B: STN group, C: Sham group), randomized, double-blind, parallel-controlled trial. PD patients in the drug-off state (≥12 hours after drug withdrawal) were randomly assigned to receive either tTIS or sham stimulation targeting GPi/STN, with each stimulation lasting 30 minutes. Clinical symptom assessments were conducted before and after the intervention, and safety was monitored by researchers throughout the process.
Eligibility Criteria
Inclusion Criteria: 1. Age \>= 40 years; 2. Meet the diagnostic criteria for primary Parkinson's disease (MDS Parkinson's Disease Diagnostic Criteria (2015 Edition)); 3. No medication adjustment in the 4 weeks before and during each stimulation; 4. MDS-UPDRS III score \>= 8 points, Hoehn-Yahr score 1-4 points Exclusion Criteria: 1. Focal brain injury or severe leukoencephalopathy (Fazekas grade 3 or above) on previous head MRI/CT scans; 2. Various secondary Parkinson's syndromes (vascular Parkinson's syndrome, drug-induced Parkinson's syndrome, etc.); 3. Severe craniocerebral trauma, cranial surgery or deep brain stimulation treatment; 4. Ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.; 5. A history of epilepsy, unexplained loss of consciousness, or taking anticonvulsant drugs for epileptic seizures; 6. Diagnosed with neuropsychiatric diseases other than Parkinson's disease; 7. A history of drug abuse or drug use; 8. Participated in any clinical trial in the past 3 months; 9. Pregnant/lactating women or subjects (including men) who plan to have children within 6 months; 10. Other situations that the researchers consider unsuitable for inclusion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07572903 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Parkinson s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07572903 currently recruiting?
Yes, NCT07572903 is actively recruiting participants. Contact the research team at 2445011385@stu.ahmu.edu.cn for enrollment information.
Where is the NCT07572903 trial being conducted?
This trial is being conducted at Hefei, China.
Who is sponsoring the NCT07572903 clinical trial?
NCT07572903 is sponsored by The First Affiliated Hospital of Anhui Medical University. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.